The National Institute of Health Research (NIHR) has launched a new page to describe its role in the use of complex innovative design studies.
“[Complex innovative design] CID trials are increasingly being used by researchers instead of traditional drug development pathways involving clinical trials from phases 1 to 4. The CID approach enables researchers to carry out more complex trials that address multiple clinical questions at once.
“For example, a drug can be simultaneously evaluated for safety and efficacy with different cancer types, and new cancer types can be added as the trial progresses. The CID approach can accelerate the traditional route to drug licensing which, in layman’s terms, means faster and more efficient ways of bringing new treatments to patients.”
The new site highlights the role of NIHR in designing and funding CID studies, and signposts users to useful resources to guide their work.
Find the new site here.